Wolfe Research downgraded Reliance Steel from Outperform to Peer Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | Underperform → Peer Perform | Wolfe Research | |
| 12/2/2024 | $341.00 | Neutral | Goldman |
| 7/26/2024 | $262.00 | Peer Perform → Underperform | Wolfe Research |
| 4/11/2024 | $380.00 | Buy → Neutral | Citigroup |
| 4/28/2023 | Outperform → Peer Perform | Wolfe Research | |
| 1/4/2023 | $231.00 | Neutral | BofA Securities |
| 10/6/2022 | $218.00 → $201.00 | Buy → Neutral | Goldman |
| 8/15/2022 | $230.00 | Outperform | BMO Capital Markets |
For Immediate Release: September 24, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA held a ribbon-cutting ceremony to highlight the completion of the 64,000 square foot expansion and renovation of the National Forensic Chemistry Center (NFCC) located in Cincinnati, Ohio. The goal of this revitalization effort was to impro